Literature DB >> 23683334

Serum cytokines associated with severity and complications of kala-azar.

Dorcas L Costa1, Regina L Rocha, Rayssa M A Carvalho, Adelino S Lima-Neto, Michael O Harhay, Carlos Henrique N Costa, Manoel Barral-Neto, Aldina P Barral.   

Abstract

OBJECTIVES: Recent clinical data suggest that severe kala-azar (or visceral leishmaniasis) is an exaggerated innate immune response mediated by inflammatory cytokines, leading to a systemic inflammatory syndrome similar to what is observed in malaria, sepsis and other diseases. We tested this hypothesis by measuring serum cytokines in individuals with kala-azar.
METHODS: We compared patients with severe kala-azar (i.e. hemorrhagic manifestations, n = 38) with patients without evidence of hemorrhage (n = 96). We conducted a detailed clinical and laboratory evaluation, measuring serum IL-1beta, IL-6, IL-8, IL-10, IL-12, interferon-gamma, and TNF-alpha, and markers of disseminated intravascular coagulation (DIC).
RESULTS: Infants had higher levels of inflammatory cytokines, while HIV-infected patients had lower concentrations of IL-10 and interferon-gamma. Higher levels of IL-6, interferon-gamma, and IL-8 were found among deceased patients. IL-8 and interferon-gamma were independently associated with bleeding. Several cytokines were associated with different signs of severe clinical and laboratory manifestations, including DIC. IL-6 was highly positively and independently associated with IL-1beta, IL-8, IL-10, and negatively associated with TNF-alpha. IL-1beta and TNF-alpha were also highly independently associated with disease severity.
CONCLUSION: In its severe form, kala-azar, a neglected tropical disease, initiates a systemic inflammatory response that leads to DIC and other manifestations. Children may have higher risk of death due to the more intense cytokine release. The data supports the notion that IL-6 is the central cytokine that is associated with lethal disease, but interferon-gamma, IL1beta, IL-8, and TNF-alpha are also involved with disease severity. Inhibition of IL-6 is a potential target of adjuvant therapy for severe or pediatric forms of this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23683334      PMCID: PMC4001482          DOI: 10.1179/2047773213Y.0000000078

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  58 in total

1.  IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis.

Authors:  O Bacellar; A D'oliveira; S Jerônimo; E M Carvalho
Journal:  Cytokine       Date:  2000-08       Impact factor: 3.861

Review 2.  IL-10, an inflammatory/inhibitory cytokine, but not always.

Authors:  Pio Conti; Duraisamy Kempuraj; Kristiana Kandere; Mario Di Gioacchino; Renato C Barbacane; Maria L Castellani; Mario Felaco; William Boucher; Richard Letourneau; Theoharis C Theoharides
Journal:  Immunol Lett       Date:  2003-04-03       Impact factor: 3.685

Review 3.  Infection and inflammation as risk factors for thrombosis and atherosclerosis.

Authors:  Marcel Levi; Tom van der Poll; Marcus Schultz
Journal:  Semin Thromb Hemost       Date:  2012-03-07       Impact factor: 4.180

Review 4.  Endothelium: interface between coagulation and inflammation.

Authors:  Marcel Levi; Hugo ten Cate; Tom van der Poll
Journal:  Crit Care Med       Date:  2002-05       Impact factor: 7.598

5.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

Review 6.  Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense.

Authors:  Adrian R L Gear; David Camerini
Journal:  Microcirculation       Date:  2003-06       Impact factor: 2.628

7.  Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil.

Authors:  G L Werneck; M S A Batista; J R B Gomes; D L Costa; C H N Costa
Journal:  Infection       Date:  2003-06       Impact factor: 3.553

8.  [Visceral leishmaniasis in children: prognostic factors].

Authors:  Mohamed Slim Abdelmoula; Zohra M'Hamdi; Fethi Amri; Néji Tebib; Hadhami Ben Turkia; Marie Françoise Ben Dridi
Journal:  Tunis Med       Date:  2003-08

Review 9.  Interferon-gamma: an overview of signals, mechanisms and functions.

Authors:  Kate Schroder; Paul J Hertzog; Timothy Ravasi; David A Hume
Journal:  J Leukoc Biol       Date:  2003-10-02       Impact factor: 4.962

10.  Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.

Authors:  Simon Collin; Robert Davidson; Koert Ritmeijer; Kees Keus; Yosef Melaku; Sammy Kipngetich; Clive Davies
Journal:  Clin Infect Dis       Date:  2004-02-12       Impact factor: 9.079

View more
  43 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Immunomodulatory and Antileishmanial Activity of Phenylpropanoid Dimers Isolated from Nectandra leucantha.

Authors:  Thais Alves da Costa-Silva; Simone S Grecco; Fernanda S de Sousa; João Henrique G Lago; Euder G A Martins; César A Terrazas; Sanjay Varikuti; Katherine L Owens; Stephen M Beverley; Abhay R Satoskar; Andre G Tempone
Journal:  J Nat Prod       Date:  2015-04-02       Impact factor: 4.050

3.  Bone marrow parasite burden among patients with New World kala-azar is associated with disease severity.

Authors:  Joyce M Silva; Danielle A Zacarias; Lívio C de Figueirêdo; Maria Regiane A Soares; Edna A Y Ishikawa; Dorcas L Costa; Carlos H N Costa
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

4.  Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.

Authors:  Vera Lucia Lanchote; Roque Almeida; Aldina Barral; Manoel Barral-Netto; Maria Paula Marques; Natália V Moraes; Angela M da Silva; Tania M V Souza; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

5.  Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells.

Authors:  Neetu Singh; Shyam Sundar
Journal:  Mol Immunol       Date:  2017-02-20       Impact factor: 4.407

6.  Comparison of serum cytokine levels in symptomatic and asymptomatic HIV-Leishmania coinfected individuals from a Brazilian visceral leishmaniasis endemic area.

Authors:  Diego Lins Guedes; Elis Dionísio da Silva; Maria Carolina Accioly Brelaz Castro; Walter Lins Barbosa Júnior; Ana Victoria Ibarra-Meneses; Achilleas Tsoumanis; Wim Adriaensen; Johan van Griensven; Valéria Rêgo Alves Pereira; Zulma Maria de Medeiros
Journal:  PLoS Negl Trop Dis       Date:  2022-06-17

7.  Preclinical diagnosis of American visceral leishmaniasis during early onset of human Leishmania (L.) infantum chagasi-infection.

Authors:  Luciana Vieira do Rêgo Lima; Patrícia Karla Santos Ramos; Marliane Batista Campos; Thiago Vasconcelos dos Santos; Claudia Maria de Castro Gomes; Márcia Dalastra Laurenti; Carlos Eduardo Pereira Corbett; Fernando Tobias Silveira
Journal:  Pathog Glob Health       Date:  2014-12-09       Impact factor: 2.894

8.  The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14.

Authors:  Priscila L Dos Santos; Fabrícia A de Oliveira; Micheli Luize B Santos; Luana Celina S Cunha; Michelle T B Lino; Michelle F S de Oliveira; Manuela O M Bomfim; Angela Maria Silva; Tatiana R de Moura; Amélia R de Jesus; Malcolm S Duthie; Steven G Reed; Roque P de Almeida
Journal:  PLoS Negl Trop Dis       Date:  2016-01-27

9.  The Nlrp3 inflammasome, IL-1β, and neutrophil recruitment are required for susceptibility to a nonhealing strain of Leishmania major in C57BL/6 mice.

Authors:  Melanie Charmoy; Benjamin P Hurrell; Audrey Romano; Sang Hun Lee; Flavia Ribeiro-Gomes; Nicolas Riteau; Katrin Mayer-Barber; Fabienne Tacchini-Cottier; David L Sacks
Journal:  Eur J Immunol       Date:  2016-01-20       Impact factor: 5.532

10.  Pharmacological evaluation of anti-arthritic potential of terpinen-4-ol using in vitro and in vivo assays.

Authors:  Sania Aslam; Waqas Younis; Muhammad Nasir Hayat Malik; Shah Jahan; Ambreen Malik Uttra; Muhammad Usman Munir; Muhammad Roman
Journal:  Inflammopharmacology       Date:  2022-03-23       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.